Yescarta’s Sales Grow; Gilead Prepares for Increased Manufacturing Demands; Tecartus’s EU Approval in R/R Adult ALL Faces Delays; Gilead’s Q4 2021 Earnings Call Summary
On Tuesday, February 1, Gilead held their Q4 2021 earnings call (press release / presentation) highlighting an increase in revenue for their cell therapy franchise and Yescarta’s anticipated approval in 2L r/r LBCL. Furthermore, management highlighted Tecartus’s (CD19 CAR-T) Type II variation in the EU for r/r adult ALL. Below, Celltelligence provides insights on how Gilead’s manufacturing strategy could position the company for success, while discussing likely US and EU approvals for Yescarta in 2L LBCL.